EMA - European Medicines Agency · March 30, 2023

PRAC starts safety review of levamisole, a medicine used to treat parasitic worm infections

EMA's Pharmacovigilance Risk Assessment Committee initiates safety review of levamisole to assess risk of leukoencephalopathy.

Low obligation Product class Pharmaceuticals EU-wide Pharmacovigilance

Review will assess risk of leukoencephalopathy, a condition affecting the brain

Read the official source ↗

Published by EMA - European Medicines Agency. HealthSignal links to the original document; the summary above is extracted from the source text.